Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 19/20 | 1.00 |
| ▸ | CCNK | O75909 | 19/20 | 1.00 |
| ▸ | CDK9 | P50750 | 19/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 19/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 17/20 | 1.00 |
| ▸ | CDK2 | P24941 | 17/20 | 1.00 |
| ▸ | CDK7 | P50613 | 10/20 | 0.80 |
| ▸ | CCNH | P51946 | 9/20 | 0.80 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.80 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24839346 | 0.89 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839559 | 0.89 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839557 | 0.88 | CCNK (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839561 | 0.87 | CCNK (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839802 | 0.86 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839571 | 0.86 | CDK7 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839843 | 0.86 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24839342 | 0.85 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL20190945 | 0.85 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29613489 | 0.85 | CCNT1 (1.00) | CCNT1CCNKCDK9CDK12CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, RB1, MKI67 | CCNT1 41/4885CCNK 10/4885CDK9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.